Bernard Coulie - Jul 11, 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
President and CEO, Director
Signature
/s/ Mike Ouimette, attorney-in-fact
Stock symbol
PLRX
Transactions as of
Jul 11, 2022
Transactions value $
-$561,509
Form type
4
Date filed
7/13/2022, 07:05 PM
Previous filing
Jun 16, 2022
Next filing
Sep 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Options Exercise $31.2K +15K +25.31% $2.08* 74.3K Jul 11, 2022 Direct F2
transaction PLRX Common Stock Sale -$338K -15K -20.2% $22.50 59.3K Jul 11, 2022 Direct F1
transaction PLRX Common Stock Options Exercise $26K +12.5K +21.09% $2.08* 71.8K Jul 12, 2022 Direct
transaction PLRX Common Stock Sale -$281K -12.5K -17.41% $22.50 59.3K Jul 12, 2022 Direct F1
holding PLRX Common Stock 449K Jul 11, 2022 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLRX Stock Option (right to buy) Options Exercise $0 -15K -4.45% $0.00 322K Jul 11, 2022 Common Stock 15K $2.08 Direct F4
transaction PLRX Stock Option (right to buy) Options Exercise $0 -12.5K -3.88% $0.00 310K Jul 12, 2022 Common Stock 12.5K $2.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
F2 Includes 4,433 shares of Common Stock acquired by the reporting person pursuant to an employee stock purchase program.
F3 Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.